Sulfisoxazole, an FDA approved antibiotic, reduced the secretion of small EVs in breast adenocarcinoma cell lines by inhibiting components of the ESCRT-dependent pathway, such as ALG-2-interacting protein X (ALIX) and VPS4B, through endothelin receptor type A (a G-protein coupled receptor) targeting and triggering co-localisation of multivesicular endosomes with lysosomes for degradation [196]. The gene discussed is PDCD6IP; the disease is breast adenocarcinoma.